Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Scrip Team

Set Alert for Articles By Scrip Team

Latest From Scrip Team

Appointments: Roche, Eli Lilly, Ipsen And Syros Make New Leadership Hires, Plus Board Appointments At EUSA, Autolus And Forendo

The latest biopharma industry personnel moves include a new executive hires at Roche, Lilly Oncology, Ipsen and Syros, a resignation at Five Prime, plus new board appointments at EUSA, Autolus and Forendo. 

Appointments BioPharmaceutical

Appointments: Changes At Merck KGaA, Servier, Unum and Aduro

The latest biopharma industry appointments include a new chief patient officer at Servier, executives at Merck KGaA, Unum and Aduro, as well as several board updates.

Appointments BioPharmaceutical

Appointments: Changes At Hikma, Bluebird Bio, Celgene, Alkermes, Cell Medica, Editas Medicine, Futura Medical, Corline Biomedical And Horizon Discovery

Pharma and biotech appointments this week include a new CEO at Hikma and an interim-CEO at Horizon Discovery, a Chief Commercial Officer for bluebird bio, and new board directors at Celgene, Alkermes, Editas Medicine, and Futura Medical.

Appointments Companies

Appointments: Changes At Axovant Sciences, Immunocore, Sangamo Therapeutics, Circassia, MaxCyte and CANbridge Life Sciences

Pharma and biotech appointments this week include a management shake up at Axovant Sciences, a new CEO at Immunocore, Sangamo's latest legal hire, and new board members at Circassia and MaxCyte.
Appointments BioPharmaceutical

Pharma Q4 Results Preview: Bristol, Allergan, Gilead, GSK, Sanofi, Teva

Hemophilia and immuno-oncology will be in the spotlight as earnings season continues into February. Will Bristol be a buyer or an acquisition target? How will Sanofi fare with its new acquisitions? And how will Teva and GSK fare as they face generics for top brands?

Sales & Earnings Business Strategies
See All